Impact News +++ SoundHound AI and LG Partner to Expand Commerce Opportunities for Merchants on LG Smart TVs (GlobeNewswire EN) +++ LG ELECTRONICS Aktie -3,93%

MADRIGAL Aktie

>MADRIGAL Aktienkurs

385.9 EUR +0.2% (TradegateBSX)

Ask: 386 EUR / 78 Stück

Bid: 380 EUR / 6 Stück

Tagesumsatz: 53 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

MADRIGAL Aktie über LYNX handeln

Intraday

1 Jahr

>MADRIGAL Performance

1 Woche: -2,8%

1 Monat: -12,7%

3 Monate: -5,3%

6 Monate: -13,2%

1 Jahr: +2,9%

laufendes Jahr: -23,3%

>MADRIGAL Aktie

Profil:

Madrigal Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with significant unmet medical need. Its lead produ..
>Volltext..

Insiderhandel:

>MADRIGAL Kennzahlen

Aktien/ Unternehmen:

Analysten:

Bewertung:

Rentabilität:

Managementeffizenz:

>MADRIGAL Peer Group

Gesundheit, Lebererkrankungen & -behandlung/ Hepatitis, Stoffwechselerkrankungen (Diabetes/ Adipositas)

>MADRIGAL Chart & Kurs - NASDAQ

>MADRIGAL News

03.11.26 - 14:06	Madrigal Pharmaceuticals: Überraschender Gewinnsprung und Blockbuster-Status für Rezdiffra treiben Aktie zweistellig an (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

03.11.26 - 13:03	Madrigal Pharmaceuticals Reports Third-Quarter 2026 Financial Results and Provides Corporate Updates (GlobeNewswire EN)
	CONSHOHOCKEN, Pa., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today reports third-quarter 2026 financial results and provides corporate updates....

27.10.26 - 16:30	Will Madrigal (MDGL) Report Negative Earnings Next Week? What You Should Know (Zacks)
	Madrigal (MDGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....

15.10.26 - 22:09

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)

CONSHOHOCKEN, Pa., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on October 1, 2026 and October 14, 2026 to a total of 26 new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan. The equity awards were approved by Madrigal's independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4)....

12.09.26 - 02:01	Insiderhandel: President and CEO verkauft Aktien von Madrigal Pharmaceuticals im Wert von 3407398 USD (Insiderkauf)
	Sibold, William John - Vorstand - Tag der Transaktion: 2026-09-09...

12.09.26 - 02:01	Insiderhandel: President and CEO verkauft Aktien von Madrigal Pharmaceuticals im Wert von 2831800 USD (Insiderkauf)
	Sibold, William John - Vorstand - Tag der Transaktion: 2026-09-11...

10.09.26 - 19:54	Madrigal skizziert Wachstumspläne für Rezdiffra und Pipeline-Strategie (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

10.09.26 - 18:36	Institutional Investors Are Loading Up on Madrigal Pharmaceuticals Stock. Should You? (Fool)
	Madrigal has a first-mover advantage in treating MASH, a type of fatty liver disease....

25.08.26 - 18:36	Here′s Exactly What It Will Take for Madrigal Pharmaceuticals Stock to Take Off (Fool)
	Rezdiffra's biggest growth opportunity may still be ahead....

21.08.26 - 06:01	Insiderhandel: General Counsel verkauft Aktien von Madrigal Pharmaceuticals im Wert von 341940 USD (Insiderkauf)
	Kelley, Shannon T. - Vorstand - Tag der Transaktion: 2026-08-17...

11.08.26 - 18:54	Madrigal auf Wachstumskonferenz: Rezdiffra beschleunigt Wachstum, Pipeline wird ausgebaut (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

06.08.26 - 14:06	Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference (GlobeNewswire EN)
	CONSHOHOCKEN, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that the company will participate in the Canaccord Genuity 46th Annual Growth Conference on Tuesday, Aug. 11, 2026 at 12:00 P.M. EDT....

31.07.26 - 19:00	MDGL Stock Down Despite Q2 Beat, MASH Drug Drives Top-Line Y/Y Growth (Zacks)
	Madrigal beats Q2 estimates as Rezdiffra sales lift revenues 71% year over year, but shares fall as investors weigh slower commercial growth....

30.07.26 - 17:51	Madrigal outlines 2027 F4c outcomes readout while reinforcing mid- to high 30s 2026 gross-to-net outlook (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

30.07.26 - 16:00	Madrigal (MDGL) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
	Madrigal (MDGL) delivered earnings and revenue surprises of +21.96% and +4.27%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?...

30.07.26 - 13:27	Madrigal Pharmaceuticals GAAP EPS of -$1.99 beats by $0.65, revenue of $364.3M beats by $11.13M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

30.07.26 - 13:03	Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates (GlobeNewswire EN)
	CONSHOHOCKEN, Pa., July 30, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today reports second-quarter 2026 financial results and provides corporate updates....

21.07.26 - 22:09

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)

CONSHOHOCKEN, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on July 15, 2026 to ten new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan. The equity awards were approved by Madrigal's independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4)....

21.07.26 - 08:01	Insiderhandel: President and CEO verkauft Aktien von Madrigal Pharmaceuticals im Wert von 1368253 USD (Insiderkauf)
	Sibold, William John - Vorstand - Tag der Transaktion: 2026-07-20...

16.07.26 - 14:03	Madrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026 (GlobeNewswire EN)
	CONSHOHOCKEN, Pa., July 16, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its second-quarter 2026 financial results on Thursday, July 30, 2026, prior to the open of the U.S. financial markets....

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Der Bock ist ein Tier, welches auch als Bier getrunken werden kann. - Wilhelm Busch

Partner: >TradegateBSX Börse | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram